Percutaneous transluminal septal alcoholization for the treatment of refractory hypertrophic obstructive cardiomyopathy. Initial experience in the Federal District

Arquivos Brasileiros de Cardiologia

Volumn 80, Issue 4, 2003, Pages 369-378

  Vidal Osterne, Evandro César ^a   Seixas, Tamer Najar ^b   Filho, Walter Paulo ^b   Cintra Osterne, Ernesto Misael ^b   Gomes, Otoni Moreira ^b  

^a SRES   (Brazil)

^b NONE

Author keywords

Ablation; Hypertrophic obstructive cardiomyopathy; Percutaneous septal ablation; Percutaneous septal alcoholization

Indexed keywords

ADULT; ARTICLE; COLOR ULTRASOUND FLOWMETRY; CORONARY ARTERY SPASM; DEATH; DISEASE CLASSIFICATION; EXPERIENCE; EXTRASYSTOLE; FEMALE; FOLLOW UP; HEART VENTRICLE SEPTUM DEFECT; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IMPLANT; MAJOR CLINICAL STUDY; MALE; PATIENT; PERCUTANEOUS TRANSLUMINAL SEPTAL ALCOHOLIZATION; RELAPSE; SURGICAL TECHNIQUE; SYMPTOM; BRAZIL; CATHETER ABLATION; DOPPLER ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART VENTRICLE SEPTUM; HYPERTROPHIC CARDIOMYOPATHY; METHODOLOGY; MIDDLE AGED; TRANSLUMINAL CORONARY ANGIOPLASTY;

ALCOHOL;

ADULT; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BRAZIL; CARDIOMYOPATHY, HYPERTROPHIC; CATHETER ABLATION; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY; ETHANOL; FEMALE; HEART SEPTUM; HUMANS; MALE; MIDDLE AGED;

EID: 4444274903     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Maron BJ, Bonow RD, Canon RD, Leon MB, Epstein SE. Hypertrophic cardiomyopathy. N Engl J Med 1987; 316: 780-9.
2. Davies MJ, MCKenna WJ. Hypertrophic cardiomyopathy: an introduction to pathology and pathogenesis. Br Heart J 1994; 72(suppl): S2-S3.
3. Marian AJ, Roberts R. Recents advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 1995; 92: 1336-47.
4. Spirito P, Seidman CE, MCKenna WJ, Maron JB. The management of hypertrophic cardiomiopathy. N Engl J Med 1997; 33: 775-85.
5. Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurusaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults: echocardiographic analysis of subjects in the Cardiac Study. Circulation 1995; 92: 785-9.
6. Watkins H. Multiple disease genes cause hypertrophic cardiomyopathy. Br Heart J 1994; 72(suppl): S4-S9.
7. Moolman JC, Corfield VA, Posen B, Ngubela K, Seidman C, Brink P. Sudden death due to troponin T mutations. J Am Coll Cardiol 1997; 29: 549-55.
8. Arteaga-Fernandez E. Cardiomiopatia hipertrófica - Estudo da sobrevida e de fatores prognósticos. (Tese de Doutorado) Faculdade de Medicina da USP. São Paulo, 1998.
9. Maron BJ, Casey AS, Poliac LC, Gohman TE, Almquist AK. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA 1999; 281: 650-5.
10. Abbasi AS, MCAlpin RN, Eber LM, Pearce ML. Echocardiographic diagnosis of idiopathic hypertrophic cardiomyopathy without outflow obstruction. Circulation 1972; 46: 897-904.
11. Jiang L, Levine RA, King ME, Weyman AE. An integrated mechanism for systolic anterior motion of the mitral valve in hypertrophic cardiomyopathy based on echocardiographic observations. Am Heart J 1987; 113: 633-44.
12. Wigle EP, Sanson Z, Henderson M, Ruddy T, Fulop J, Rakowisky H. Hypertrophic cardiomyopathy: the importance of the site and extent of hypertrophy: a review. Prog Cardiovasc Dis 1986; 28: 1-83.
13. Blanchard DG, Ross J. Jr. Hypertrophic cardiomyopathy: prognosis with medical or surgical therapy. Clin Cardiol 1991; 14: 11-9.
14. Rosing D, Keny K, Bores J, Maron BJ, Epstein SE. Verapaniil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. 1-Hemodynamic effects. Circulation 1979; 60: 1201-8.
15. Pollick C, Gershony G, Szarga C, Wogle ED. Dysopiramide: hemodynamic effects in hypertrophic cardiomyopathy (abstract). Circulation 1983; 68(suppl. 3): 161.
16. Anderson D, Ralff G, Ports T, Brundage B, Parmley W, Chaterjee K. Hypertrophic obstructive cardiomyopathy. Effects ofacute and chronic verapamil treatment on left ventricular systolic and diastolic function. Br Heart J 1984; 51: 523-9.
17. Spirito P, Maron BJ, Bonow RO, Epstein SE. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in patients with hypertrophic cardiomyopathy. Am J Cardiol 1987; 60: 123-9.
18. MCKenna WJ, Harris L, Rowland E. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. Br Heart J 1985; 53: 412-6.
19. Fannanapazir L, Leon MB, Bonow RO, Tracy CM, Cannon RO, Epstein SE. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991; 67: 169-74.
20. Wigle ED, Rakowsky H, Kimballi BP, Williams WG. Hypertrophic Cardiomyopathy: clinical spectrum and treatment. Circulation 1995; 92: 1680-92.
21. Jeanrenaud X, Goy JJ, Kappenberger I. Effects of dual-chamber pacing in hypertrophic obstructive myocardiopathy. Lancet 1992; 339: 1318-23.
22. Fananapazir L, Epstein ND, Curiel RV. Long-term results of dual chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvment and reduction of left ventricular hypertrophy. Circulation 1994; 90: 2731-42.
23. Kappenberger I, Linde C, Daubert C. Pacing for obstructive hypertrophic cardiomyopathy. Eur Heart J 1997; 18: 1249-56.
24. Nishimura RA, Hayes DL, Ilstrup DM. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy: acute doppler echocardiographic and catheterization hemodynamic study. J Am Coll Cardiol 1996; 27: 421-30.
25. Nishimura RA, Trusty JM, Hayes DL. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double blind, crossover trial. J Am Coll Cardiol 1997; 29: 435-41.
26. Maron BJ, Nishimura RA, MCKenna WJ, Rakowsky H. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy (The M-Pathy Study). Circulation 1999; 99: 2927-33.
27. Morrow AG, Reitz BA, Epstein SE. Operative treatment in hypertrophic subaortic stenosis: techniques and the resultsof pre and postoperative assessments in 83 patients. Circulation 1975; 52: 88-102.
28. Seiler C, Hesse OM, Schoenbeck M. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. J Am Coll Cardiol 1991; 17: 634-42.
29. MCCully RB, Nishimura RA, Rajik AJ. Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy. Circulation 1996; 94: 467-71.
30. MCintosh CL, Maron BJ. Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulation 1988; 78: 487-95.
31. Mohr R, Schaff HV, Danielson GK, Puga FJ, Pluth IR, Tajik AJ. The outcome of surgical treatment of hypertrophic obstructive myocardiopathy: experience over 15 years. J Thorac Cardiovasc Surg 1989; 97: 666-74.
32. Chahine RA. Surgical versus medical treatment of hypertrophic cardiomyopathy: is the perspective changing? J Am Coll Cardiol 1991; 17: 643-5.
33. Cooley DA, Leachman RD, Wukach DC. Difuse muscular subaortic stenosis: surgical treatment. Am J Cardiol 1973; 31: 1-6.
34. MCintosh CL, Maron JB. Current operative treatment of obstructive hypertrophic cardiomyopathy. Circulation 1988; 78: 487-95.
35. Krajcer Z, Leachman R, Cooley DA, Coronado R. Septal myotomy-miectomy versus mitral valve replacement in hypertrophic cardiomyopathy: ten year follow-up in 185 patients. Circulation 1989; 80(suppl. I): 57-64.
36. Sigwart Y. Non surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995; 346: 211-4.
37. Kuhn H, Gietzen F, Lenner CH, Gerenkamp T. Induction of subaortic septal ischemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Eur Heart J 1997; 18: 846-51.
38. Knight C, Kurbaan A, Seggewiss U, Henein M, Gunning M, Harrington D. Non surgical septal reduction for hypertrophic obstructive cardiomyopathy. Circulation 1997; 95: 2075-81.
39. Marin Neto JA, Lima Filho MO, Schumidt A, Maciel BC. Cardiomiopatia hipertrófica tratada por técnica intervencionista de redução septal. Arq Bras Cardiol 1998; 70: 343-50.
40. Seggewiss H, Faber L, Gleichmann U. Percutaneous transluminal septal ablation in hypertrophic obstructive cardiomyopathy. Thorac Cardiovasc Surg 1999; 47: 84-100.
41. Colombo A, Airoldi F, Di Mario C, Catanoso A, Tolaro S. Progressive decrease of outflow gradient and septum thickness after percutaneous alcoholization of interventricular septum in hypertrophic obstructive cardiomyopathy. Ital Heart J 2000; 1: 200-6.
42. Oomann A, Ramachandran P, Osmann M. Percutaneous transluminal septal myocardial ablation in drug-resistant hypertrophic obstructive cardiomyopathy. J Invasive Cardiol 2001; 13: 526-30.
43. Esteves MAB, De Matos RB, Lima Filho A. Oclusão da artéria septal na cardiomiopatia hipertrófica obstrutiva. Rev Bras Cardiol Invas 2001; 9: 20-3.
44. Kuhn H, Gietzen F, Schafers M. Catheter interventional therapy of hypertrophic obstructive cardiomyopathy by transcoronary ablation of septum hypertrophy: changes of subaortic septum. Eur Heart J 1997; 18(suppl): 605-8.
45. Gleichmann U, Seggewiss H, Faber L. Kathetertherapie der hypertrophen obstruktiven Kardiomyopathie. Detsch Med Wochenschr 1996; 21: 679-85.
46. Faber L, Meissner A, Ziemsen P. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long-term follow-up of the first series of 25 patients. Heart 2000; 83: 326-31.
47. Lakkis NM, Nagueh SF, Dunn JK. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol 2000; 36: 852-5.
48. Spirito P, Rapezzi C, Autuore C. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994; 90: 2743-7.
49. Kuhn H. Transcoronary ablation of septal hypertrophy (TASH): a 5-year experience. J Cardiol 2000; 89: 559-64.
50. Sherif FN, Steve RO, Nasser ML, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 2001; 38: 1701-6.
51. Kurbaan AS, Seggewiss H, Henein MY. Non-surgical septal reduction for hypertrophic obstructive cardiomyopathy: long term follow-up of the early patients. Circulation 1997; 96(suppl): 2587A.
52. Gietzen F. Acute and long term results after transcoronary ablation of septal hypertrophy (TASH), catheter interventional treatment for hypertrophic cardiomyopathy. Eur Heart J 1999; 20: 1342-54.
53. Cano MN, Cano SJF, Oliveira DC, et al. Ablação percutânea da artéria septal no tratamento da cardiomiopatia hipertrófica. Rev Bras Cardiol Invas 2001; 9: 13-8.
54. Conselho Nacional de Saúde. Resolução N° 196 de 10 de Outubro de 1996. In: Diretrizes éticas internacionais para pesquisas biomédicas envolvendo seres humanos. Bioética 1996; 3: 95-126.